Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) have been assigned an average recommendation of “Hold” from the eight ratings firms that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, six have given a hold rating and one has assigned a strong buy rating to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $36.50.

LKFT has been the subject of several recent research reports. UBS Group reiterated a “market perform” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a research note on Tuesday, February 24th. Weiss Ratings reiterated a “hold (c)” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a research note on Tuesday, May 26th. Zacks Research upgraded shares of Lakefront Biotherapeutics American Depositary Shares from a “strong sell” rating to a “hold” rating in a research note on Monday, June 8th. Wall Street Zen downgraded shares of Lakefront Biotherapeutics American Depositary Shares from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. Finally, Royal Bank Of Canada lifted their target price on shares of Lakefront Biotherapeutics American Depositary Shares from $32.00 to $33.00 and gave the stock a “sector perform” rating in a research note on Tuesday, February 24th.

Hedge Funds Weigh In On Lakefront Biotherapeutics American Depositary Shares

Large investors have recently modified their holdings of the business. State of Wyoming purchased a new position in shares of Lakefront Biotherapeutics American Depositary Shares in the second quarter worth about $28,000. Van ECK Associates Corp boosted its position in shares of Lakefront Biotherapeutics American Depositary Shares by 61.6% in the fourth quarter. Van ECK Associates Corp now owns 1,968 shares of the biotechnology company’s stock valued at $64,000 after acquiring an additional 750 shares during the period. Arax Advisory Partners boosted its position in shares of Lakefront Biotherapeutics American Depositary Shares by 319.2% in the fourth quarter. Arax Advisory Partners now owns 2,335 shares of the biotechnology company’s stock valued at $76,000 after acquiring an additional 1,778 shares during the period. Quadrant Capital Group LLC bought a new position in shares of Lakefront Biotherapeutics American Depositary Shares in the third quarter valued at approximately $134,000. Finally, Squarepoint Ops LLC bought a new position in shares of Lakefront Biotherapeutics American Depositary Shares in the third quarter valued at approximately $211,000. Hedge funds and other institutional investors own 32.46% of the company’s stock.

Lakefront Biotherapeutics American Depositary Shares Stock Performance

NASDAQ LKFT opened at $28.30 on Monday. Lakefront Biotherapeutics American Depositary Shares has a 52-week low of $26.42 and a 52-week high of $37.78. The company has a 50-day simple moving average of $28.15 and a 200 day simple moving average of $31.06. The company has a market capitalization of $1.86 billion, a PE ratio of -20.07 and a beta of 0.26.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last posted its earnings results on Sunday, February 15th. The biotechnology company reported $13.92 earnings per share for the quarter. The business had revenue of $1.06 billion during the quarter. As a group, analysts forecast that Lakefront Biotherapeutics American Depositary Shares will post -6.32 EPS for the current fiscal year.

Lakefront Biotherapeutics American Depositary Shares Company Profile

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.